CClinicalTrials.gg
RecruitingNCT07527624ImagineLaSuiteUpdated Apr 14, 2026

Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability

An observational study in Rare Diseases, sponsored by Imagine Institute. Recruiting at 1 site in France. Open to participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Imagine Institute · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
15 Years to 25 Years
Sex
All
01

Study summary

Rare diseases are often synonymous with difficulties for sufferers, whether physical, mental or social. Patients suffering from rare diseases face specific problems, such as the long wait for a diagnosis, the geographical distance between the rare disease reference center and home, and the isolation created by this very disabling disease... Children suffering from rare genetic diseases have difficulty accessing higher education, but above all in finding an internship or work-study placement, due to the rarity of their disability.

The aim of this study, entitled "Imagine La Suite", is to assess the difficulties encountered by young people with rare genetic diseases and disabilities in their search for vocational and university training or employment.

02

Conditions studied

  • Rare Diseases

Browse trials for

03

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients currently aged 15-25 born between 1997 and 2007 and followed at Necker in the networks of the following disease reference centers:

  • epilepsy without deficiency ;
  • genodermatosis ;
  • constitutional bone diseases ;
  • craniofacial malformations;
  • deafness;

Inclusion criteria

  • Current age 15-25 years born between 1997 and 2007
  • Rare genetic disease confirmed by a genetic test, originating in childhood and followed at Necker in the networks of the following disease reference centers:

    • epilepsy without deficiency ;
    • genodermatosis ;
    • constitutional bone diseases ;
    • craniofacial malformations;
    • deafness;

Exclusion criteria

Exclusion Criteria:

  • Patient or parent's opposition to study participation
  • Patient with intellectual disability (IQ \< 70)
  • Patients with pathologies involving intellectual disability and patients with a clinical sign of intellectual disability.
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Interventions

  • Othersurvey

    Patients take part in a survey, completing a form in less than 30 minutes

05

What researchers measure

Primary outcomes

  1. Entry into a training program, validation of a diploma, obtaining a 1st stable job

    Time frame: 18 Months

Secondary outcomes

  1. Characterize the pathology components of the care pathway, barriers/ strengths to inclusion

    Time frame: 18 Months

  2. Use of tools to facilitate socio-professional inclusion

    Time frame: 18 Months

  3. Number of HR company representatives made aware of rare diseases

    Time frame: 18 Months

06

Study locations

1 of 1 sites recruiting
  • Imagine Clinical Research
    Paris, Île-de-France Region 75015, France
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07527624
Lead sponsor
Imagine Institute
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Jan 8, 2024
Primary completion
Jun 8, 2026 (estimated)
Completion
Aug 8, 2026 (estimated)
Last update
Apr 14, 2026

Study contacts

Fatima clinical project manager, Medical doctor
Contact
recherche-clinique@institutimagine.org
+33 (0)1 42 75 45 65

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion